Salsalate, is a nonsteroidal anti-inflammatory agent for oral administration.
Carefully consider the potential benefits and risks of Salsalate tablets, USP and other treatment options before deciding to use Salsalate tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see
WARNINGS). Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder.
Media Articles Related to Salsalate
Source: MedicineNet Osteoarthritis Specialty [2016.11.08]
Title: Osteoarthritis Symptoms
Category: Doctor's & Expert's views on Symptoms
Created: 7/16/2013 12:00:00 AM
Last Editorial Review: 11/8/2016 12:00:00 AM
Osteoarthritis: New blood test detects early stages, study finds
Source: Arthritis / Rheumatology News From Medical News Today [2016.10.28]
Profiles of altered amino acids in the blood distinguish early stage osteoarthritis from rheumatoid arthritis and other joint diseases, study shows.
Patients report symptom improvement following prolotherapy for knee osteoarthritis
Source: Arthritis / Rheumatology News From Medical News Today [2016.10.27]
Prolotherapy, an injection-based complementary treatment for symptomatic knee osteoarthritis, was associated with improved knee-specific symptoms, quality of life, and ability to participate in...
Slideshow: Exercises for Knee Osteoarthritis and Joint Pain
Source: MedicineNet Degenerative Disc Specialty [2016.09.22]
Title: Slideshow: Exercises for Knee Osteoarthritis and Joint Pain
Created: 2/18/2010 12:54:00 PM
Last Editorial Review: 9/22/2016 12:00:00 AM
Slideshow: Exercises for Osteoarthritis -- Yoga, Swimming, & More
Source: MedicineNet Osteoarthritis Specialty [2016.09.22]
Title: Slideshow: Exercises for Osteoarthritis -- Yoga, Swimming, & More
Created: 3/23/2012 12:00:00 AM
Last Editorial Review: 9/22/2016 12:00:00 AM
Published Studies Related to Salsalate
The effect of salsalate therapy on endothelial function in a broad range of
CONCLUSIONS: Salsalate therapy, particularly when therapeutic salicylate levels
Salsalate improves glycemic control in patients with newly diagnosed type 2 diabetes. [2011.09.22]
Chronic inflammation contributes to insulin resistance and type 2 diabetes mellitus (T2DM). We investigated whether treatment with salsalate, an anti-inflammatory medication, improves glycemia in a group of newly diagnosed drug-naive patients with T2DM... The results show that salsalate is effective in improving glycemic control in newly diagnosed naive patients with T2DM.
Stimulation of human whole-body energy expenditure by salsalate is fueled by higher lipid oxidation under fasting conditions and by higher oxidative glucose disposal under insulin-stimulated conditions. [2011.05]
OBJECTIVE: Nonsteroidal antiinflammatory drugs appear to improve insulin sensitivity and are currently tested in clinical trials. Salsalate, however, may blunt mitochondrial function, an unwarranted side effect for type 2 diabetics. We examined the effect of salsalate on ex vivo mitochondrial function and lipid-induced insulin resistance... CONCLUSION: We conclude that salsalate failed to improve whole-body insulin sensitivity but increased basal fat oxidation and insulin-stimulated CHOox, indicating improved metabolic flexibility. The beneficial effects of salsalate on CHOox can be attributed to elevated insulin levels. Mitochondrial respirometry revealed no indications that the changes in substrate selection and EE could be attributed to changes in skeletal muscle mitochondrial capacity or mitochondrial coupling.
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. [2010.03.16]
BACKGROUND: Salsalate, a nonacetylated prodrug of salicylate, has been shown to decrease blood glucose concentration in small studies. OBJECTIVE: To compare the efficacy and safety of salsalate at different doses in patients with type 2 diabetes... CONCLUSION: Salsalate lowers HbA1c levels and improves other markers of glycemic control in patients with type 2 diabetes and may therefore provide a new avenue for treatment. Renal and cardiac safety of the drug require further evaluation. PRIMARY FUNDING SOURCE: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.
The effect of salsalate on insulin action and glucose tolerance in obese non-diabetic patients: results of a randomised double-blind placebo-controlled study. [2009.03]
AIM/HYPOTHESIS: Low-grade inflammation may contribute to obesity-related insulin resistance and has been associated with increased risk of type 2 diabetes mellitus. The present study evaluated whether treatment with salsalate, a traditional anti-inflammatory medication, would improve insulin action in obese non-diabetic individuals... INTERPRETATION: The glucose-lowering potential of salicylates appears to be due to effects on insulin concentration rather than improved insulin action. Salicylate-based compounds may be useful for the treatment and prevention of type 2 diabetes.
Clinical Trials Related to Salsalate
Salsalate for Insulin Resistance in Schizophrenia [Completed]
Being obese is a common problem for people with schizophrenia. People with schizophrenia
are more likely to be overweight compared to the general population. Being overweight is a
major risk factor for developing type II diabetes. Approximately 15% of people with
schizophrenia have type II diabetes. People with type II diabetes have problems with their
body's insulin. Insulin is a hormone produced by the body to control blood sugar level.
Obesity and type II diabetes are strong risk factors for heart disease. In type II diabetes
the body does not respond to insulin correctly. Obesity, type II diabetes, and insulin
resistance are all common states of inflammation. Inflammation is a reaction by the body to
irritation, injury, or infection.
Salicylates are non-steroidal anti-inflammatory drugs. Aspirin is an example of a
salicylate. These drugs work by decreasing the level of inflammation in the body.
Salicylates have been shown to decrease inflammation and improve the body's response to
insulin. Improving the body's response to insulin and decreasing inflammation could
possibly reduce the risk of developing type II diabetes. Salicylates have been known for
years to be effective for the treatment of diabetes. Salicylates increase the body's
response to insulin causing blood sugar levels to decrease. Many salicylate drugs have side
effects including stomach irritation and increased risk of bleeding. The drug for this
study is called salsalate and is different from other salicylates. Salsalate has a lower
bleeding risk than aspirin. Salsalate has been used to treat arthritis and has been shown
to be safe.
There have been no studies using salsalate in people with schizophrenia. The purpose of
this study is to gain experience in the use of salsalate in people with schizophrenia. The
study would be a pilot study to obtain preliminary data. The study would be a 6-week study
where everyone in the study would receive the drug salsalate. The participants in the study
will have tests of baseline symptoms of schizophrenia, a physical exam, EKG (to check heart
function), and a side effect checklist for possible side effects from salsalate. The study
will also have some blood drawn to measure blood sugar levels, insulin levels, and
Targeting Inflammation Using Salsalate in CardioVascular Disease [Active, not recruiting]
The hypothesis is that western lifestyle, with sedentary behaviors and caloric excess
promote a chronic, subacute inflammatory state that participates in the development and
progression of atherosclerosis. We will evaluate the effects of targeting inflammation
using the anti-inflammatory drug salsalate, compared to placebo, on coronary artery plaque
volume assessed by multi-detector computed tomographic angiography (MDCTA). The TINSAL-CVD
study is a randomized, double-masked, placebo-controlled, 2 arm, clinical trial.
The purpose of the study is to compare the effect of salsalate or placebo on sub-acute
inflammation and coronary plaque, in people with cardiovascular disease. Participants are
randomized to active intervention (salsalate) or placebo interventions for a period of 30
months. The primary endpoint is change in plaque volume in the coronary arteries assessed
by MDCTA from baseline to 30 months.
Safety and Efficacy of Salsalate to Treat Endothelial Dysfunction in HIV-infected Adults [Completed]
This is a phase II, open label, randomized-controlled pilot study designed to study both the
efficacy and safety of salsalate in decreasing endothelial cell dysfunction, systemic
inflammation, and insulin resistance in HIV-infected adults. The investigators hypothesis
is that salsalate will reduce inflammation and therefore endothelial cell activation and
insulin resistance. The sample size will be 40, with an equal number of people being
randomized to one of two groups. The first arm will be randomized to salsalate therapy.
The second arm will act as a control group. The study duration will be 13 weeks.
Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D) [Completed]
Growing evidence over recent years supports a potential role for low grade chronic
inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study
we will determine whether salsalate, a member of the commonly used Non-Steroidal
Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type
2 diabetes. The study will determine whether salicylates represent a new pharmacological
option for diabetes management. The study is conducted in two stages. The first stage is
a dose ranging study, administering salsalate compared to placebo over three months. The
primary objective of Stage 2 of the study is to evaluate the effects of salsalate on blood
sugar control in diabetes; the tolerability of salsalate use in patients with type 2
diabetes (T2D); and the effects of salsalate on measures of inflammation, the metabolic
syndrome, and cardiac risk.
The second stage is a second trial and posted under alternate registration.
Pilot Study to Determine Effects of Salsalate in Type 1 Diabetes and Painful Peripheral Neuropathy [Completed]
This 12 week study will examine the effects of daily Salsalate treatment on markers of
neuropathic pain and intra-epidermal nerve fiber density. the study is being done in people
with type 1 diabetes with signs and symptoms of peripheral neuropathy.
Reports of Suspected Salsalate Side Effects
Drug Ineffective (5),
Burning Sensation (4),
Grip Strength Decreased (4),
Gait Disturbance (4),
Diabetes Mellitus (3),
Thyroid Cancer (3), more >>
Page last updated: 2016-11-08